National Institutes of Health United States

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

Open Health Posted 3 Nov 2026

Deadline 16 Nov 2029 1099 days left

Overview

Funding agency: National Institutes of Health HHS-NIH11
Reference: PAR-28-042
Funding programme: Health
Funding instrument: Cooperative agreement
Cost sharing: Not required
Region: United States
Applicants based in: United States
Source: Grants.gov (US Federal)

About the funder

Funder: National Institutes of Health Research council, United States
Grants in 2025: 129 Typical grant $700k
Open calls: 646 open calls Giving history, how to apply, and Follow on the funder page

Description

The purpose of the Notice of Funding Opportunity (NOFO) is to support the analytical and clinical validation of molecular, cellular, and imaging biomarkers and assays for cancer detection, diagnosis, prognosis, monitoring, prediction of response or resistance to treatment, cancer prevention and control, as well as pharmacodynamic markers and markers of toxicity. Utilizing either a phased UH2/UH3…

Sign up to view full grant details

Create a free account to unlock the complete grant description, funding details, eligibility criteria, and application links.

Full description Funding amounts & eligibility Application links & deadlines Save & track grants

Overview

About the funder

Description

Sign up to view full grant details

Related grants

Send to CRM

CRM Integration Required

Email Grant